FilingSEC EDGAR6-K
Agomab Initiates Phase 2b Study of Ontunisertib in Fibrostenosing Crohn's Disease
· SEC accepted
StagePhase 2b
Filing content
Agomab dosed the first patient in its global Phase 2b study of ontunisertib for fibrostenosing Crohn's disease, triggering a €7 million milestone payment.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…